ATS
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Author home page(s):
Viking O. Björk
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Björk, V. O.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Björk, V. O.

Ann Thorac Surg 1990;50:151-154
© 1990 The Society of Thoracic Surgeons


Articles

Development of an artificial heart valve

Viking O. Björk, MD*,a,b

a Karolinska Hospital, Stockholm, Sweden
b Desert Heart Institute Foundation, Rancho Mirage, California USA

* Address reprint requests to Dr Björk, c/o Frid, Runbergsy 8, 19148 Sollentuna, Sweden.

When I reviewed the 21-year results with the Björk-Shiley tilting disc valves, I found out that to date, we still have to use these disc valves and all mechanical heart valves with anticoagulation therapy. The highest incidence of valve-related postoperative deaths after aortic valve replacements in Stockholm was anticoagulation-related bleeding, which continued at a rate of about 1% year after year. There is a need to improve the quality of life for heart valve patients, especially for children, for young females who want to have children, for the older generation who are on medical treatment, and for all patients in whom long-term anticoagulation of a perfect quality is impossible to guarantee. A series of tests on goats has been performed, using the Björk-Shiley Monostrut valve used in 2,024 patients at the Karolinska Hospital in Stockholm and in 75,000 patients worldwide for up to 8 years with a modification of a microporous surface. In the mitral position, this modified partially microporous-surfaced Björk-Shiley Monostrut valve has permitted goats to live for 5 years with four normal pregnancies without anticoagulation therapy.




This article has been cited by other articles:


Home page
Asian Cardiovascular and Thoracic AnnalsHome page
S. John, C. John, K. Saha, B. V. Velaikodeth, and E. Ravikumar
A Quarter Century Experience with Mitral Valve Replacement
Asian Cardiovascular and Thoracic Annals, December 1, 1996; 4(4): 201 - 205.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 1990 by The Society of Thoracic Surgeons.